Analysis of Medical Use and Costs Related to the Management of Liver Cirrhosis Using National Patients Sample Data

환자표본자료를 이용한 간경변증 환자의 의료이용 특성 및 의료비용 분석

  • Received : 2016.08.28
  • Accepted : 2016.10.24
  • Published : 2016.12.31


Background: Liver cirrhosis causes substantial socio-economic burden and is one of the major severe liver diseases in Korea. Nonetheless, there is only a few studies that analyzes disease burden of liver cirrhosis in Korea. Such study must be carried out due to its increasing need from the invention of new drugs for chronic hepatitis and demand for cost-effectiveness analyses. Methods: Patient sample data with ensured representativeness was analyzed retrospectively to compare the medical costs and uses for patients with compensated cirrhosis and decompensated cirrhosis. Patient claims data that include K74 and K703 from the year of 2014 were selected. Within the selected data, decompensated cirrhosis patient was identified if complications such as ascites (R18), encephalopathy (B190), hepatic failure (K72), peritonitis (K65), or esophageal varices (I85) were included, and they were compared to compensated cirrhosis patients. Results: 6,565 patients were included in the analysis. The average cost per patient was 6,471,020 (SD 8,848,899) KRW and 2,173,203 (4,220,942) KRW for decompensated cirrhosis and compensated cirrhosis, respectively. For inpatients, the average hospitalized days was 38.0 (56.4) days and 27.2 (57.2) days for decompensated cirrhosis and compensated cirrhosis, respectively. For outpatients, the average number of visits was 8.7 (9.1) days and 5.3 (7.5) days for compensated cirrhosis and decompensated cirrhosis, respectively. Conclusion: Compared to compensated cirrhosis patients, decompensated cirrhosis patients had higher costs, especially for hospitalization, injection, examination, and drugs administrated within medical institutions.



Supported by : 보건복지부


  1. The Korean Association for the Study of the Liver and liver cirrhosis clinical research center. Clinical Practice Guideline for Liver Cirrhosis, Update. Seoul: Jin-corp, 2011; 1-83.
  2. The Korean Association for the Study of the Liver, White Paper on Liver Diseases in Korea, Seoul: The Korean Association for the Study of the Liver, 2013.
  3. HIRA. Healthcare Bigdata Hub. Available from Accessed July 14, 2016.
  4. Abergel A, Rotily M, Branchoux S, et al. Chronic hepatitis C: Burden of disease and cost associated with hospitalisations in France in 2012 (The HEPC-LONE study). Clin Res Hepatol Gastroenterol 2016; 40(3): 340-8.
  5. Kieran JA, Norris S, O'Leary A, et al. Hepatitis C in the era of directacting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study. BMC infect Dis 2015;15:471.
  6. Stahmeyer JT, Rossol S, Bert F, et al. Cost of treating hepatitis C in Germany: a retrospective multicenter analysis. Eur J Gastroenterol Hepatol 2014;26(11):1278-85.
  7. Thongsawat S, Piratvisuth T, Pramoolsinsap C, et al. Resource Utilization and Direct Medical Costs of Chronic Hepatitis C in Thailand: A Heavy but Manageable Economic Burden. Clin Res Hepatol Gastroenterol 2014;3:12-8.
  8. Zhang S, Ma Q, Liang S, et al. Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China. J Viral Hepat 2016;23(3):202-10.
  9. Lu J, Xu A, Wang J, et al. Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China. BMC Health Serv Res 2013;13:37.
  10. Lim SJ, Jo JH, Kim SH, Status of health insurance system and reform trend in major foreign countries, Seoul: National Health Insurance Service, 2014;1-126.
  11. Lee H, Shin E, Lee C, et al. Medical price levels of OECD countries: A Comparative Study. Research Institute for Healthcare Policy. 2012;11:1-62.
  12. Kwon S, Kim S, Kim T, et al. Comparison of domestic and foreign generic drug prices. National Health Insurance Service?Health Insurance Review and Assessment Service. 2010.
  13. Kim S. Pharmaceutical pricing policies in a global market. OECD health policy studies. 2011.
  14. Lee E, Kim H, Kim B et al. Comparative analysis of drug price level in Korea compared to OECD countries. Sungkyunkwan University? Korean Research-based Pharma Industry Association. 2014.
  15. Kim do Y, Yoon KT, Kim W, et al. Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea. Medicine 2016;95(30):e3896.
  16. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370(16):1483-93.
  17. Leleu H, Blachier M, Rosa I. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat 2015; 22(4):376-83.
  18. Linas BP, Barter DM, Morgan JR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 2015;162(9):619-29.
  19. Petta S, Cabibbo G, Enea M, et al. Cost-effectiveness of sofosbuvirbased triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014;59(5):1692-705.
  20. Pfeil AM, Reich O, Guerra IM, et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in swiss patients with chronic hepatitis C. PloS one 2015;10(5):e0126984.
  21. San Miguel R, Gimeno-Ballester V, Blazquez A, et al. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut 2014.
  22. Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007;11(11):1-205, iii.
  23. Siebert U and Sroczynski G. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care 2005;21(1):55-65.
  24. Wright M, Grieve R, Roberts J, et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006;10(21):1-113, iii.
  25. The Korean Association for the Study of the Liver. Chronic Hepatitis Clinical Practice Guideline. 2015.
  26. El Khoury AC, Wallace C, Klimack WK, et al. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. J Med Econ 2012;15(5):887-96.
  27. Kim Y, Shin S, Park J, et al. Costing methods in Healthcare. National Evidence-based Healthcare Collaborating Agency 2013.
  28. Shon C, Choi HY, Shim JJ, et al. The Economic Burden of Hepatitis A, B, and C in South Korea. Jpn J Infect Dis 2016;69(1): 18-27.
  29. Chen GF, Wei L, Chen J, et al. Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. PloS one 2016;11(6):e0155934.
  30. Chhatwal J, He T, Hur C, et al. Direct-acting antiviral agents for patients with hepatitis C virus genotype 1 infection are cost saving. Clin Gastroenterol Hepatol 2016.
  31. Virabhak S, Yasui K, Yamazaki K, et al. Cost-effectiveness of directacting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatmentnaive and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. J Med Econ 2016;19(12):1144-56.
  32. Lee S, Chung W, Hyun KR. Socioeconomic costs of liver disease in Korea. Korean J Hepatol 2011;17(4):274-91.